Category Archives: Genome

Reported sales nil

For the full year,net loss reported to Rs 0.01 crore in the year ended March 2022 as against net loss of Rs 0.56 crore during the previous year ended March 2021. Sales declined 66.67% to Rs 0.07 crore in the year ended March 2022 as against Rs 0.21 crore during the previous year ended March 2021.ParticularsQuarter EndedYear EndedMar. 2022Mar. 2021% Var.Mar. 2022Mar. 2021% Var.Sales00.02 -100 0.070.21 -67 OPM %0-500.00 --542.86-61.90 - PBDT-0.31-0.28 -11 -0.34-0.31 -10 PBT-0.26-0.32 19 -0.42-0.50 16 NP0.15-0.38 LP -0.01-0.56 98

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, May 30 2022. 09:38 IST

Read the original:
Genomic Valley Biotech reports standalone net profit of Rs 0.15 crore in the March 2022 quarter - Business Standard

Genome scientist Evan Eichler and global health researcher Tulio de Oliveira have been named to 2022 TIME100. This is the magazines annual list of the hundred most influential people over the past year.

The full list and related tributes will appear on newsstands Friday, May 27, in the June 6/June 12 issue, and can now be viewed online at time.com/time 100. This is the nineteenth annual compilation of the list, which recognizes the impact of the worlds most influential people during the past year.

Eichler is a professor of genome sciences at the University of School of Medicine and a Howard Hughes Medical Institute Investigator. de Oliveira is an affiliate professor of global health, a joint UW medical school and UW School of Public Health department. His main faculty appointment is at the University of KwaZulu-Natal in South Africa. He is director of CERI (Centre for Epidemic Response & Innovation) and also founded KRISP, a state-of-the-art scientific facility in Africa created to support public health responses. KRISP is a partner in the global UWARN communicable disease outbreak monitoring network coordinated at the UW.

Evan Eichler, genome scientist noted for advancing comparative sequencing of human and primate genomes

Eichler, and the multi-university research group of Karen Miga, Adam Phillipy, and Michael Schatz, were honored together as a team in the Innovation category.They are credited with leading the recent effort to complete a gapless human reference genome.The achievement was published in Science April 1, along with a series of scientific papers analyzing different aspects of the finished genome.The work was the culmination of a large consortium, the Telomore-to-Telomere orT2T, which aimed to complete sequences of all 23 human chromosomes, end-to-end. Please see related news release.

A TIME tribute to the project team was written by Jennifer Doudna, a 2020 Nobel Laureate in Chemistry recognized for her work on CRISPR-Casp gene editing. She pointed out the significance of their recent achievement in advancing understanding of human evolution, common and rare diseases, and the structure and function of the human genome.

Eichlers lab and his graduate students, alongsidetheir work on the overall human genome completion project, contributed to advances in gene sequencing technology and analytics that allowed scientist to delve into difficult to decipher areas of the human genome. These regions were found to contain new information about what makes us distinctly human, in comparison to other primates. Their findings also provided insights into primate evolution. Other T2T studies in his lab are clarifying the structure and function of centromeres, which are critical for the accurate segregation of genetic material during cell division.

Among the many intriguing findings of the Eichler lab were certain human-only areas of repeated code. These human-specific areas of segmental duplication are reservoirs for new genes that drive the formation of more neurons and increase connectivity among synapses in the frontal cortex of the brain. This is the part of the brain where reasoning, logic and language functions take place.

Eichler was part of the original Human Genome Project back in 2001. He was fascinated by regions of the genome that were complex from the perspective that they were highly repetitive, but also encoded genes. Ever since the Human Genome Project was concluded, he had an intense desire to finish those parts of the genome that were felt to be inaccessible at that time. Now, he says, is not the end, as scientists have only finished a human genome. He looks forward to the completion of other human genomes to better showcase the diversity of humanity encoded in genome variation.

Global health emerging disease researcher Tulio de Oliveira

Bioinformatics expert Tulio de Oliveira was honored with Sikhulile Moyo, his former Ph.D. student, in the Pioneering category. Moyo is the director of the lab in Botswana that was among the first to detect the Omicron variant of the coronavirus that causes COVID-19. The discovery occurred during their routine analysis of the virus genetic materials in positive patient samples. The full sequences of genetic data allowed them to look for any evolutionary changes in the virus currently being transmitted. They were alarmed to see that some of the samples contained heavily mutated viruses far more than previous variants. He reported the sequences to the Botswana Ministry of Health and Wellness, and discussed the matter with de Oliveira in South Africa, who was also seeing strange mutations. Africa publicly reported the genetic and epidemiological findings on the new strain, which was later named Omicron, to the rest of the world.

de Oliveira has worked on viral outbreaks for more than 20 years. These included HIV, Hepatitis B and C, Zika, Yellow Fever, Dengue, Chikungunya, Dengue and SARS-CoV-2, the pandemic coronavirus. He is the former director of the Genomics Program at the Wellcome Trust Africa Centre for Health and Population Studies in South Africa.

de Oliveira is based at one of the seven international partner sites for UWARN, a National Institutes of Health-funded center at the UW. UWARN is a world network of researchers who share their latest information to stay on top of emerging and reemerging pathogens, and their evolving variants. Their goal is to detect potential outbreaks occurring in various parts of the world, information that could assist various agencies in mitigation efforts.

A tribute to the two global health leaders was written for the 2022 TIME100 by John Nkengasong, a Cameroonian virologist who is serving as the first director of the African Centers for Disease Control and Prevention. He applauded them for their remarkable contributions to the understanding of COVID-19 variants in the world.

de Oliveira was one of 10scientists listed in Nature in2021 for their outstanding scientific developments. Hewas also named inMIT Technology Review as one of the leaders of the 10 breakthrough technologies of2022. This same year, he received the Gold Medal Award from the South African Medical Research Council, and, for his contributions to society, the Batho Pele Award from the Government of South Africa.

The human genome team and the COVID-19 variant team join a wide variety of people who have had tremendous influence on the world in government leadership, arts, entertainment, science and medicine, sports, social movements, and many other areas. Some of the others on this years list are Ukrainian President Volodymyr Zelenskyy; Olympic gold-medal figure skater Nathan Chen; European Commission President Ursula von der Leyen; Tanzania President Samia Suluhu Hassan: musician and Oscar-winning filmmaker Ahmir Questlove Thompson, Brazilian indigenous activist and environmentalist Snia Guajajara; U.S. President Joe Biden; Vice Premier of the Peoples Republic of China Sun Chunlan; Excutive Director of the Transgender Education Network of Texas Emmett Schelling; American TV host Oprah Winfrey; and Apple CEO Tim Cook.

Follow @TIME #TIME100 for updates about the list on Twitter and Instagram and at Facebook.com/TIME.

Read the rest here:
Genome and global health scientists on TIME100 - UW Medicine Newsroom

Thermo Fisher Scientific and Qatar Genome Program Partner to Advance Precision Medicine

The collaboration includes custom genotyping arrays designed to accelerate genomic research and clinical applications of predictive genomics across Arab populations

WALTHAM, Mass. (May 23, 2022) Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally.

Under the agreement, Thermo Fisher and Qatar Genome Program will develop an Axiom* custom genotyping array for pan-Arab populations using whole genome sequencing data from 19 Arab countries. The array, with about 800,000 variants, aims to help drive scientific research and insights into conditions including diabetes, cardiovascular and metabolic diseases, autism, inherited genetic disorders and cancer. Once available through Thermo Fishers global commercial channels in late 2022, the array is intended to provide a cost-effective alternative to whole genome sequencing for Arab populations, enabling increased diversity in large genome-wide studies.

Qatars national vision is to provide a high standard of living for our people, and that includes providing access to genomics data, technology and insights to improve population health across the country, said Dr. Radja Badji, genome operations manager at Qatar Genome Program. Our collaboration with Thermo Fisher will not only help us advance precision medicine in Qatar but also among people of Arab identity worldwide.

Thermo Fisher began working with Qatar Genome Program in 2018 to establish the first microarray designed specifically for the Qatari population. The Q-Chip detects genetic alterations that increase individuals risk of both prevalent and rare diseases. As part of the new agreement, the organizations will continue to refine algorithms and define clinically actionable content to assess polygenic risk scores, a measure of disease risk, and clinically relevant variants, including those related to pharmacogenomics.

Thermo Fishers Axiom microarray technology is designed to help accelerate precision medicine, and we are honored to partner with the Qatar Genome Program as they take bold steps to leverage the power of genomics to improve the standard of care for human health, said Chad Carter, vice president and general manager of microarray genetic solutions at Thermo Fisher Scientific. Together, were creating building blocks for implementing comprehensive precision medicine initiatives at scale for population health.

Thermo Fisher provides a range of predictive genomics solutions used globally to assess gene-related disease risk and drug response. For more information, please visit thermofisher.com/predictive-genomics.

*For research use only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit http://www.thermofisher.com.

About the Qatar Genome Program

The Qatar Genome Program is an ambitious population-based project aimed at positioning Qatar among the pioneering countries in the implementation of precision medicine. Whole genome sequencing and other omics data is being combined with phenotypic data within the Qatar Biobank, providing a resource for breakthrough research discoveries and to help policy makers set future healthcare priorities for Qatar.

Qatar Foundation Unlocking Human Potential

Qatar Foundation for Education, Science and Community Development (QF) is a non-profit organization that supports Qatar on its journey to becoming a diversified and sustainable economy. QF strives to serve the people of Qatar and beyond by providing specialized programs across its innovation-focused ecosystem of education, research and development, and community development.

QF was founded in 1995 by His Highness Sheikh Hamad bin Khalifa Al Thani, the Father Amir, and Her Highness Sheikha Moza bint Nasser, who shared the vision to provide Qatar with quality education. Today, QFs world-class education system offers lifelong learning opportunities to community members as young as six months through to doctoral level, enabling graduates to thrive in a global environment and contribute to the nations development.

QF is also creating a multidisciplinary innovation hub in Qatar, where homegrown researchers are working to address local and global challenges. By promoting a culture of lifelong learning and fostering social engagement through programs that embody Qatari culture, QF is committed to empowering the local community and contributing to a better world for all.

For a complete list of QFs initiatives and projects, please visit: http://www.qf.org.qa

To stay up to date on our social media activities, follow our accounts on: Instagram, Facebook, Twitter and LinkedIn.

For any media inquiries, please contact: pressoffice@qf.org.qa

Go here to read the rest:
Thermo Fisher Scientific and Qatar Genome Program Partner to Advance Precision Medicine - Bio-IT World

Bees are, in many ways, the darlings of the insect world. Not only do they play a crucial role in thriving ecosystems, but theyre also harbingers of the worsening consequences of climate change.

To bolster our knowledge of bee biology and behavior, a new effort dubbed the Beenome100 Project is building a first-of-its-kind library of dozens of different bee genomes. Researchers can use that information to tackle big picture questions like how to protect these tiny creatures, and how theyve evolved alongside us over time.

Beenome is just one of the many initiatives affiliated with the Earth BioGenome Project (EBP), an ambitious international effort to sequence the genomes of nearly 2 million named eukaryotic species. Eukaryotes have cells that contain nuclei and other organelles, setting them apart from other life forms like bacteria. This domain covers all plants, fungi, and animals, including bees.

READ MORE: World isnt meeting biodiversity goals, U.N. report finds

First launched in 2018, EBP aims to sequence the genomes of those species over the course of 10 years, housing them in a public database so that all researchers can have unfettered access to this extensive, unprecedented data. The sweeping project is largely made possible thanks to advancements in the field of genomic sequencing technology, which has made this work faster, cheaper and more accessible in recent years.

Bees face myriad threats in a warming world, including population decline, a loss of synchronicity with the flowers they pollinate and increased susceptibility to disease. In general, insects are vulnerable to climate change because being coldblooded makes them uniquely sensitive to temperature fluctuations, said Michael Branstetter, a research entomologist at the United States Department of Agriculture.

The extinction rate of insect species is eight times faster compared to mammals, birds and reptiles, according to the United Nations Environment Program, and if the total mass of insects continues to drop at its current annual rate, these creatures could vanish within a century. Bees are no exception to our own peril. Around a third of the crops we eat rely on animal pollinators, according to the USDA. Without bees, birds and other creatures, our pantries and refrigerators would look dramatically different.

If you picked any insect group to disappear, you wouldnt want to start with bees, because we would feel the effects for sure, Branstetter said.

The United States is home to approximately 4,000 native bee species, and the aim of Beenome is to help researchers answer such questions as the genetic underpinnings that make different species susceptible to climate change. The project has a goal of unlocking the blueprint for at least 100 species, and eventually sequencing more over time, said Jay Evans, a research entomologist at the USDA and co-lead of the project.

The broader Earth BioGenome Project will help map a massive branch on the tree of life, with many potential uses, like significantly improving our understanding of evolution and ecology. It will also inform research in fields like agriculture, medicine, biotechnology and more. But the reality of climate change is putting researchers feet to the fire.

Around 1 million animal and plant species face extinction, several potentially within the next few decades, due to forces like habitat loss and rising global temperatures, the United Nations estimates. That means Earth could lose up to 50 percent of its total biodiversity by 2100 without human intervention, according to the University of California, Davis.

For pollinator species, shifting temperatures and weather patterns shift also affect the natural timetables long adhered to by flowering plants a serious disadvantage to both the plant and the insects.

There are many reasons why genomes are useful tools for scientific research, Branstetter said, including assessing the genetic diversity of a species and identifying potential genomic signatures of sociality that underpin some species hive mentality. But the very real threat of losing entire species to environmental changes is also a consideration.

Should a species go extinct, its at least nice to know that weve documented the genome of that species, Branstetter added.

When it comes to pollination, some bees are generalists who will pollinate pretty much any flower they come across. Others specialize in specific botanical families or even species, and have evolved over time in ways that optimize their ability to retrieve pollen from their preferred plants.

One example of this is South Africas Rediviva bee, which specializes in the collection of oils from snapdragons. The relationship is an example of a bee adapting over time to be an ideal match for the flowers they frequent.

The spurs on the flowers that the bees stick their legs into vary in length, and theyve sort of co-evolved with the bees, Branstetter said. So the bees front legs also vary in length. That matched variation allows for greater efficiency of the pollinating process, a benefit to both the bees and the snapdragons.

Anna Childers co-leads the USDAs Ag100Pest Initiative sequencing arthropods like ticks, flies and weevils. She noted that its crucial to understand how bees, as sentinel insects of climate change, may be responding to fluctuating temperatures and seasons in order for us to protect potentially endangered species.

We kind of need to know how climate change might affect them, and having their genome is one way of learning this, she said.

So how does genetic code, gibberish to the untrained eye, help answer major questions?

Childers knows that peoples eyes tend to glaze over once you get into the alphabet soup (adenine, guanine, thymine and cytosine or A, G, T and C) that comprises genomes. Thats why she likes to use the metaphor of a map.

Genomes are like the most bare-boned map, where the basic geographic features are laid out but not much else. With a little more information, Childers said, you can start to add details like the locations of homes and businesses, or the traffic patterns of the busiest neighborhoods that differ depending on the time of day.

By bringing it all together in one place and having that map on which to place [other information,] it allows us to have a much more intricate understanding of whats happening, Childers said.

So far, members of 40 species are on their way to having their genomes sequenced. These bees were picked out of their natural environments, then frozen and sent to Hawaii-based labs tasked with extracting their DNA. It may sound counterintuitive to sacrifice the bees scientists aim to preserve, but dont worry they dont take enough individuals to harm the species as a whole.

Sample collection can be tricky first researchers have to actually find a member of the bee species theyre seeking to sample in the wild. For larger bees, a single part of their body like the thorax is usually enough to get a whole genome. But the tinier the bee, the more you need to retrieve genetic code.

WATCH: As bee populations decline, can technology help fill the gap?

For the small bees, theres only enough DNA if you do the whole bee. We just grind up wings, everything all together, Evans said.

Sometimes researchers can also take multiple bees from the same colony or location and pool them together to generate a genome, Branstetter noted.

Once DNA is extracted from Beenome bees in Hawaii, researchers there or in Mississippi (both locations have the technology) feed it to a sequencing machine in smaller portions.

You break that DNA down a little bit to maybe 20,000 base pair chunks. Then you put tags on the ends of each of those chunks, and then those are what go into this sequencing machine, Evans said.

After that, those sequenced chunks get stitched together in a process called assembly. The annotation phase comes next. Thats when a combination of researchers and automated analyses interpret stretches of genetic code to figure out which genes they correspond to.

The process, which concerns about a tenth of the total genome, cross references the genomes of other species to identify the genes that are shared across different forms of life. Other parts of the genome are assessed as well, including non-coding RNA and sites that regulate how genes are turned on.

The process of annotating is akin to noting those traffic patterns or key landmarks on a map. Once its complete, the seemingly endless series of four letters is transformed into a key that connects an organisms DNA to what researchers can observe about how a living member of the species goes about its daily life.

Bees captivate researchers for almost as many reasons as there are kinds of bees. For one, their behavior varies wildly across species. Some are social like the famously hive-minded honeybees and bumblebees but the majority lead solitary lives. Theres even variation within the same species in terms of living a social or solo life depending on external factors, noted Branstetter, who is involved with Beenome.

In the U.S., the Mojave poppy bee is native to a small, arid range across parts of Utah, Nevada and California. This tiny, solitary bee which belongs to a family that had not been sequenced previously specializes in pollinating local poppies that really only grow in certain conditions, and bloom for a short period during the spring.

Perdita meconis, otherwise known as the Mojave poppy bee, is pictured beside a dime to indicate its small size. Photo by Chelsey Ritner/USDA-ARS.

Their symbiosis is a prime example of how specialized the relationship between certain bees and plants can become, and just how crucial their mutual survival is. Both the bee and one of the flowers it frequents are under consideration for the endangered species list and face the threats of urbanization in their native habitat.

When Branstetters team sent the bees genome for sequencing, he said the result was one of the best genomes of a solitary bee generated thus far. He noted that the species unique biology and habitat checks a lot of boxes when it comes to the study of bees and their conservation.

Its a really tiny bee, so it was sort of challenging methodologically to see, Can we get a good genome from it?' he said. And its from the desert Southwest, so it covers a geographic region and a habitat that we dont have many representatives of for bees.

The researchers intend to collect more Mojave poppy bees in order to improve their understanding of the populations genetic diversity, but last year they didnt find a single specimen, illustrating just how tricky that field work can be. Branstetter hopes thats an example of bet hedging, when bees skip a season of poor, dry weather conditions so that they can reappear the following year.

Bee genomes can also help us map humans shared history with the rest of the natural world. Margarita Lpez-Uribe, an associate professor of entomology at Penn State University, worked with her team to sequence the squash bee genome, a species that specializes in the pollination of members of the cucurbita genus, including squash and pumpkins.

Although squash bees can be found across the U.S. today, they were originally native to southwestern parts of the country, plus modern-day Mexico. They happily feasted on wild cucurbita plants that Indigenous populations in those regions began domesticating 10,000 years ago. But as people migrated away from that region and the scale of agriculture increased over the course of millennia, they brought their cultivated cucurbits with them, and the squash bees followed suit.

This bee had been moving with the cultivation of crops and the movement of humans throughout North America, Lpez-Uribe said.

Squash bees are pictured collecting nectar inside a squash blossom. Photo courtesy Laura Jones.

By using a combination of different genomic information, she and her team estimated when geographically separated squash bees split off from each other. The squash bees that now live in the Northeast are genetically highly divergent, Lpez-Uribe said, compared to the ancestral populations that still live in the southwest and Mexico. That means that squash bees have gone through major adaptive processes in their journey across land and time.

Its clear that genomes can help us solve mysteries of evolution and ecology. But we can also call on them to help solve some of the most pressing crises facing humanity. Childers pointed to a beetle whose genomic sequence allowed researchers to understand how its able to break down wood. That kind of information, she noted, could help us identify more efficient ways to do the same thing in order to develop alternate fuels, or clean up environmental damage caused by catastrophes like oil spills.

Its hard to know what species were going to pluck out of the environment that lead us to the innovations that will transform the future, Childers said. Having a bank of genomes at our fingertips is key to unlocking that wealth.

View post:
What genetic sequencing can reveal about the secret lives of bees - PBS NewsHour

Will invest $250,000 in companies advancing genome engineering technology and science

PRINCETON, N.J., May 24, 2022 /PRNewswire/ -- The venture capital firm SOSV and its startup development program IndieBio, have teamed up with the Genome Project-write (GP-write), a global nonprofit genome engineering consortium, to launch the GP-write Startup Team, a project designed to vet, select, fund, and advise new ventures advancing the technology and science of writing genomes. The aim of the partnership is to improve access to R&D resources for viable startups in this space and increase visibility to their important work.

SOSV'S INDIEBIO AND GENOME PROJECT-WRITE PARTNER TO FUND AND ADVISE STARTUPSWill invest $250,000 to winning applicants

The partnership will provide GP-write companies with the unique opportunity for funding and advising from the GP-write Startup Team of world leaders. Selected companies will be invited to participate in the next IndieBio cohort to receive programming, network access, mentorship, and guidance from industrial experts, biotech founders, and patent licensing experts so the startups can quickly advance toward a next round of financing.

Investing in revolutionary technology that promises the betterment of humanity and the planet, SOSV has $1.2 billion in assets under management. From SOSV, IndieBio's pre-seed life-science startups receive a $275,000 investment (up to $500,000 or more with follow-on support) and join a four-month program that provides on-site expertise, access to modern laboratories, and an unparalleled mentor network. IndieBio's San Francisco and New York programs each run two, 15-company cohorts each per year. The first round of GP-write startup companies will join the IndieBio September 2022 cohort.

"SOSV's IndieBio and GP-write have a shared visionto expedite advances in large-scale genome editing and synthesisand believe the evolution of these technologies will lead to transformational change in personalized therapeutics," said IndieBio General Partner Stephen Chambers. "Our goal is to support developments in personalized gene and cellular therapies to drive dramatic cost reductions, create solutions for reversing climate change, and produce an entirely new class of engineered materials."

"The GP-write Startup Team includes world leaders across academia and industry with a track record of successful entrepreneurship in synthetic biology.We are thrilled to be uniting in this effort, which pairs GP-write's mission with the SOSV-IndieBio expertise in startup innovation," said Amy Cayne Schwartz, President and General Counsel of GP-write. "Translating valuable innovation from academia to the marketplace for the benefit of society at large is the impetus for this Startup Partnership."

Specifically, the Request For Proposals (RFP) is seeking to fund innovative, early stage startups advancing the science and technology of genome engineering. Some high priority areas include: Software Tools for Gene/Genome-Scale Design, Improvements in DNA Synthesis, Genome Editing (e.g. expand multiplexity and precision of DNA editing), or Chromosome and Organism Engineering. To learn more or submit a proposal before July 1, 2022, email amy@engineeringbiologycenter.org.

About SOSV

SOSV is a global venture capital firm headquartered in Princeton, NJ. The firm has more $1.2 billion in assets under management and specializes in the early stage development of deep tech companies focused on human and planetary health. SOSV operates the startup development programs HAX(hard tech), IndieBio(life sciences), Chinacceleratorand MOX (cross-border growth), and dlab(blockchain). To learn more, go tohttps://sosv.com/.

About IndieBio

SOSV's IndieBio is the leading life sciences startup program. With locations in New York City and San Francisco, IndieBio's mission is to turn scientists into entrepreneurs who can save lives and save the planet. IndieBio is devoted to building early stage startups that are solving humanity's most pressing problems with climate technology, synthetic biology, alternative foods, health tech, and much more. To learn more, go to https://indiebio.co/.

About Genome Project-write

GP-write, conceived as a sequel to The Human Genome Project, leverages advances in high throughput genome sequencing, gene editing and synthetic biology to drive dramatic cost reductions and expedite whole-genome writing and redesign. Supporting work of multi-institutional and interdisciplinary research teams engaged in broad public outreach, the organization includes nearly 300 scientists, affiliated with more than 100 institutions/companies in 17 countries. GP-write's Foundry and Startup Ecosystem is led by the GPW Industrial Advisory Board comprised of world leaders in genome editing and synthesis technologies.To learn more, follow GP-write: http://www.engineeringbiologycenter.org.

View original content:https://www.prnewswire.com/news-releases/sosvs-indiebio-and-genome-project-write-partner-to-fund-and-advise-startups-301553921.html

SOURCE SOSV

View post:
SOSV'S INDIEBIO AND GENOME PROJECT-WRITE PARTNER TO FUND AND ADVISE STARTUPS - Kilgore News Herald

Complete mitochondrial genome assembly

The mitogenomes of St, Sc, and StSc were assembled into five to two subgenomes through de novo assembly using 5.3 to 6.6Gb PE reads. Each assembly was validated by conducting PCR analysis and sequencing (Tables S1 and S2, Fig. S1). The St mitogenome size was 756,058bp, and it was composed of five circular subgenomes of lengths 49,230 to 297,014bp. The total number of non-redundant genes was 78, consisting of 37 PCGs, 19 ORFs, 3 rRNAs, and 19 tRNAs (Table 1, Fig. S2A). The Sc mitogenome was 552,103bp in size with two subgenomes (338,427 and 213,676bp). The total number of non-redundant genes was 77, consisting of 37 PCGs, 20 ORFs, 3 rRNAs, and 17 tRNAs (Table 1, Fig. S2B). The StSc mitogenomes were 447,645bp in size with a major circular DNA of 398,439bp and a minor subgenome of 49,206bp. The total number of non-redundant genes was 77, consisting of 37 PCGs, 20 ORFs, 3 rRNAs, and 17 tRNAs (Table 1, Fig. S2C).

A total of 71 genes were shared among the three mitogenomes. Some genes were unique in each mitogenome: four ORFs (orf131, orf 190, orf 240, and orf 279), and three tRNAs (trnI-GAU, trnL-CAA, and trnV-GAC) were unique in the St mitogenome; five ORFs (orf109d, orf111, orf140, orf185, orf240) and one tRNA (trnfM-CAT) were unique in the Sc genome; and five ORFs (orf111, orf127, orf131, orf140, orf185) and one tRNA (trnV-GAC) were unique in the StSc mitogenome (Table 2).

Mitochondrial plastid DNA (MTPT) has been reported in various plants, such as Amborella trichopoda, Zea mays (maize), and Cynanchum wilfordii34,35,36. The degree of MTPT was examined by sequence comparison with the S. tuberosum plastome sequence (GenBank accession No. no. KM489056)37. Consequently, the St, Sc, and StSc mitogenomes were approximately 1.08.0%, 2.98.0%, and 3.14.0% considered as MTPT, respectively. Overall, approximately 1.08.0% were identified as MTPT (Table 1, Fig. S2).

Further, nuclear mitochondrial DNA (NUMT) has also been reported in various plants, such as Arabidopsis thaliana and Cucumis sativus (cucumber)38,39. NUMT was identified by sequence comparison with the S. tuberosum nuclear genome sequence (SolTub_3.0, https://www.ncbi.nlm.nih.gov/assembly/GCF_000226075.1/). Consequently, the St, Sc, and StSc mitogenomes were approximately 17.257.7%, 16.117.4%, and 10.116.3%, respectively, which were considered to be derived from or transferred to nuclear genomes accordingly. Overall, approximately 10.757.7% was identified as NUMTs. A total of 57.7% was identified in St subgenome 4, which has a very small genome size (Table 1, Fig. S2).

Homologous recombination (HR) can be mediated by repeat sequences in St, Sc, and StSc mitogenomes. The St, Sc, and StSc mitogenomes accounted for approximately 2.219.4%, 4.821.3%, and 5.725.9% of repeat sequences in which the repeat ratio was also positively correlated with the subgenome size (Table 1, Figs.1 and S2). The five St subgenomes exhibited diverse numbers of dispersed repeats: 300 (mitogenome coverage: 19.4%), 211 (15.2%), 41 (5.5%), 18 (2.2%), and 39 (4.9%) in each subgenome (Tables 1 and S5, Figs.1A and S2A). The two Sc subgenomes included 460 (25.9%) and 198 dispersed repeats (15.2%) (Tables 1 and S5, Figs.1B and S2B). Further, the two StSc subgenomes contained 480 (21.3%) and 39 (4.8%) dispersed repeats (Tables 1 and S5, Fig.1C and S2C). In contrast, tandem repeats were selected with adjacent sequences of at least two copies and up to 50bp. The St, Sc, and StSc mitogenomes had only 17, 20, and 16 tandem repeats, respectively (Table S6).

Chord diagram of three Solanum mitogenomes. (AC) represent the homologous regions of the subgenomes. R1 to R3 represent the large repeats that might cause homologous recombination among the corresponding subgenomes. St: S. tuberosum accession no. PT56, Sc: S. commersonii accession no. Lz3.2, StSc: somatic hybrid accession no. HA06-9.

Two large repeats (more than 1kb) were identified in the St subgenome 1. R1 was 11,916bp, and R2 was 7500bp. In contrast, St subgenome 2 had only R1, and subgenome 3 had only 1589bp of R3. Similarly, the R1 sequence co-existed in St subgenomes 1 and 2. The R2 repeat is shared between subgenomes 1 and 4 (Table S5, Figs.1 and S2), which might contribute to the HR between different subgenomes. The Sc mitogenomes had two multipartite structures, in which three large repeats of more than 1kb were identified (R1: 16,857bp, R2: 10,094bp, and R3: 1024bp), which might contribute to recombination events between subgenomes (Table S5, Figs.1 and S2). The StSc mitogenomes contain four large repeats (more than 1kb) (R1, 11,916bp; R2, 11,846bp; R3, 1643bp; and R4, 1024bp) that might contribute to subgenome reshuffling (Table S5, Figs.1 and S2).

We compared plastomes, mitogenomes, and nrDNAs among St, Sc, and StSc genomes. The StSc plastome was identical to Sc plastome37. Meanwhile, the StSc mitogenome shows a complicated structure with unique genes derived from both species (Table S3, Fig.2). Among 71 common genes, 21 PCGs (nad3, nad4, nad4L, nad5, nad6, sdh3, cox2, cox3, atp1, atp4, atp8, atp9, ccmB, rps3, rps4, rps12, rps13, rpl5, rpl10, rpl16, and mttB) were found identical across the three mitogenomes (denoted as green boxes on Fig.2) and their origin in the StSc genome could not be determined; 12 PCGs (nad1, nad2, nad7, nad9, sdh4, cob, cox1, ccmC, ccmFc, rps10, rpl2, and matR) were found identical with Sc (represented as sky-blue boxes in Fig.2) and 2 PCGs (atp6 and ccmFN) were identical with St (pink boxes in Fig.2). Therefore, it is likely that the majority of the somatic hybrid mitogenomes originated from Sc (Fig.2).

The origin of mitogenome recombination block in somatic hybrid (StSc) (A) Subgenome 1 of somatic hybrid mitogenome (B) Subgenome 2 of somatic hybrid mitogenome. The pink and sky-blue triangles on the black middle line indicate genes derived from S. tuberosum and S. commersonii, respectively. The green diamond boxes indicate genes of unknown origin.

GISH data using Sc genome probes revealed strong signals in 24 chromosomes but weak signals in the other 24 chromosomes in the StSc somatic hybrid (Fig.3A). We also assembled and compared 45S nrDNA cistron sequence of three species. For example, multiple aligned position at 191bp represents T genotype in St and C genotype in Sc. However, in StSc, it was identified that 75.6% of T and 24.4% of C were present. In conclusion, the overall 45S nrDNA sequences of StSc revealed both genotypes with average about 70 and 30 ratio for Sc and St, respectively (Fig.3B).

Detection of nuclear genome fusion in somatic hybrid. (A) GISH analysis of somatic hybrid (HA06-1 clone) using S. tuberosum specific-probes. The red signal of 24 arrows indicates the S. commersonii nuclear subgenomic distribution. (B) Schematic diagram of 45S ribosomal DNA cistron of Solanum species. StSc summary represents the percentage of St or Sc genotypes in the 45SnrDNA sequence.

In summary, St, a dihaploid of tetraploid cultivated potato, has five mitogenomes. Sc, a diploid wild potato, has two mitogenomes. Somatic hybrids developed via protoplast fusion of these two diploids contain the Sc-unique plastome37 but recombined mitogenomes and nuclear genomes derived from both St and Sc genomes (Fig.4).

Schematic diagram of mitogenome in parental species and their somatic hybrids. (A) S. tuberosum (St), (B) S. commersonii (Sc), and (C) somatic hybrid (StSc). S. tuberosum and S. commersonii have five and two subgenomes, respectively, which are fused into two subgenomes in the somatic hybrid generated by protoplast fusion. The origin of chloroplast genome in somatic hybrid has been determined based on sequence comparison among chloroplast genome sequences of parental species and that of the somatic hybrid.

A total of 35 PCGs were common across Solanaceae. The nonsynonymous substitution (Ka), synonymous substitution (Ks), and their ratios were calculated. The Ka values ranged from 0 to 0.119 with a 0.003 of median value. The nad4 and nad4L genes had the lowest Ka values, while atp6 had the highest Ka value. The Ks values ranged from 0.02 to 0.228 with a 0.01 of median value. Moreover, mttB and atp6 had the lowest and highest Ks values, respectively. Lastly, the Ka/Ks values ranged from 0 to 3.528 with a median value of 0.286 (Table S8, Fig.5A). A Ka/Ks value of more than 2 was observed due to the extremely low Ks value.

Mitochondrial gene diversity in Solanaceae family. (A) non-synonymous substitution (Ka) and synonymous substitution (Ks) values among the 12 Solanaceae species. Ka and Ks values were calculated with 35 protein-coding genes by CodeML program. (B) Variations of atp6 are shown by the phylogenetic tree and multiple comparisons of amino acid sequences. The conserved domain has been determined through NCBI BLASTP search.

Although the Ka and Ks values were generally low, ccmFc and mttB exhibited high Ka/Ks values of more than 1, indicating that these genes were positively selected during evolution (Fig.5A). Considering that atp6 showed a high mutation rate above 0.1. Ka and Ks values relative to the other genes, the amino-acid sequences corresponding to atp6 were compared among Solanaceae species, which revealed that amino acid sequences were variable at the N-terminus but conserved at the C-terminus (Fig.5B).

Phylogenetic trees were constructed using various programs, including RAxML, MEGA7, PhyML, and BEAST to examine the topology of the species. Trees treated with RAxML, PhyML, and BEAST displayed the same topology, while those treated with MEGA7 exhibited slightly different topologies (Fig. S3). In trees generated using RAxML representing an optimized topology (Figs.6 and S3), Solanaceae species were divided into two subfamilies, Solanoideae and Nicotianoideae, and the somatic hybrid exhibited a moderate branch between St and Sc. During the evolution of Solanaceae mitogenome, first, rps1 and rps19 were present in Solanaceae, however, these were omitted completely in Oleaceae. Next, rps7 was confirmed to be completely deleted in Solanaceae compared to Oleaceae. Lastly, ycf14 in all Nicotianoideae species was pseudogenized in the divergence period between Solanoideae and Nicotianoideae (Fig.6).

Phylogenetic relationship of 13 Solanaceae species using 35 protein-coding gene sequences commonly conserved in mitogenomes. The maximum likelihood tree was constructed using RAxML program with GTR++I model (based on jModelTest2) and a bootstrapping value of 1000. The bootstrap value (>=0.5) is shown on the node. Deleted genes and pseudogenes specifically within each group in the tree have been also shown by red and black boxes, respectively. Olea europaea in the Oleaceae family has been used as an out-group.

Here is the original post:
Mitochondrial genome recombination in somatic hybrids of Solanum commersonii and S. tuberosum | Scientific Reports - Nature.com

Lead development candidate SG-5-00455 shows potential to become first in class PAI-1/2 inhibitor that directly targets mucosal healing in patients with inflammatory bowel disease (IBD)

BRISBANE, Calif., May 24, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented data demonstrating the Company'sdevelopment candidate, SG-5-00455, improves epithelial barrier function and promotes mucosal healing by effectively inhibiting plasminogen activator inhibitor (PAI)-1/2 activity in the intestines. The data were presented at Digestive Disease Week 2022 Annual Meeting, held May 21-24 virtually and in San Diego, California.

Second Genome Logo (PRNewsfoto/Second Genome)

There is a strong correlation between the upregulation of SERPINE1 (PAI-1) and chronic inflammation in IBD. Local delivery of SG-5-00455 to the gastrointestinal mucosa of diseased mice demonstrated efficacy by inhibiting PAI-1 activity, which in excessive amounts adversely impacts wound healing, immune cell modulation and tissue remodeling. By selectively targeting the PAI-1 pathway at the mucosa, SG-5-00455 improves epithelial barrier function by regulating extracellular matrix production and reducing profibrotic inflammation. SG-5-00455 demonstrates the potential to directly target mucosal healing, a key therapeutic goal in the treatment of IBD," said Joseph Dal Proto, Ph.D. "SG-5-00455 has the potential to become a first-in-class treatment for patients with IBD in which mucosal healing is inadequately addressed by current standards of care."

This data was presented during a poster session at DDW 2022. The information is provided below:

Session Title: Non-Immune Cells in Intestinal Inflammation: Epithelium and StromaAbstract Number: 3698252Title: Identification and Development of a 1st in Class Naturally-Derived Protein that Drives Mucosal Healing and is Orally Delivered by an Engineered Cellular Therapy Targeting the Gastro-Intestinal Tract

Story continues

In addition to SG-5-00455, Second Genome has presented data on the identification of immunomodulatory peptides with therapeutic potential using their proprietary technology-enabled platform (abstract number: 3699744) which was presented during another poster session at DDW 2022.

SG-5-00455 is an orally delivered, engineered biotherapeutic modulator of the PAI1/2 pathway that is designed to work locally within the gastrointestinal tract to promote mucosal healing and improve barrier function in IBD patients. In vitro, SG-5-00455 demonstrated direct binding to PAI-1, functional inhibition of PAI-1/2 function and improvement in epithelial barrier function. In pre-clinical colitis models, oral administration of SG-5-00455 reduced pathology scores for inflammation and restored barrier function levels, as well as improved dysregulated tissue repair and fibrosis-associated gene expression and proteins levels. Mechanism of action studies revealed interaction with, and modulation of, fibrinolysis pathway members, which were found to be upregulated in IBD patient samples in multiple clinical cohorts. This will provide the basis for a potential biomarker to identify patients likely to respond to SG-5-00455. SG-5-00455 is currently in IND-enabling studies, and the Company anticipates filing an investigational new drug (IND) application with the U.S. FDA late 2022.

The SG-5-00455 poster (#3698252) entitled, "Identification and Development of a 1st in Class Naturally-Derived Protein that Drives Mucosal Healing and is Orally Delivered by an Engineered Cellular Therapy Targeting the Gastro-Intestinal Tract," and the poster on the identification of immunomodulatory peptides utilizing our proprietary technology-enabled drug discovery platform (#3699744) will be made available on the Company's website at https://www.secondgenome.com/events/.

About Second Genome

Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational precision therapies based on novel microbial genetic insights. We built a proprietary drug discovery platform with machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis and gene-editing that we couple with traditional drug development approaches to progress the development of precision therapies for wide-ranging diseases. Second Genome is advancing lead programs in IBD and cancer into IND-enabling studies. We also collaborate with industry, academic and governmental partners to leverage our platform and data science capabilities. We hold a strategic collaboration with Gilead Sciences, Inc., utilizing our proprietary platform and comprehensive data sets to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. We also hold a strategic collaboration with Pfizer (formerly Arena Pharmaceuticals) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. For more information, please visit http://www.secondgenome.com.

Investor / Media Contact:650-440-4606partnering@secondgenome.com

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/second-genome-presents-new-data-at-digestive-disease-week-ddw-2022-demonstrating-that-sg-5-00455-a-potential-first-in-class-precision-therapeutic-improves-epithelial-barrier-function-and-promotes-mucosal-healing-in-inflammator-301553343.html

SOURCE Second Genome

Continue reading here:
Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic,...

New research led by a University of Florida scientist shows a development regulator can help plants grow. In the bigger picture, the studys results also may help genome editing and, as a result, plant breeding.

Development regulators are genes that regulate plant development and growth. UF/IFAS scientists have discovered that one such gene can help deliver DNA into a plant to promote shoot growth from either a stem of a whole plant or young leaves cultured in a petri dish.

The study shows that injecting a plant developmental regulator known as PLT5 into the stem helps some snapdragons and tomatoes grow into new shoots. In addition, scientists found that the PLT5 can help young leaves or petioles of cabbages grow into a whole plant after culturing them in the petri dish.

Generally, it is extremely difficult for cells from some plants to grow into whole plants from a tissue culture, said Alfred Huo, an assistant professor of horticultural sciences at the UF/IFAS Mid-Florida Research and Education Center. By applying PLT5, scientists can more effectively deliver genes or DNA fragments into plant cells, which means plants can grow from the cellular level to adulthood more efficiently.

This research can help scientists address some questions in basic plant breeding, including how to get certain genes into plants, Huo said. It can also help scientists as they apply genome editing to many plant species.

This finding can accelerate a breeding program, Huo said. You want to use genome editing for plant breeding. But you need to deliver a genome editing toolbox into plants to make the editing happen. With this process, scientists can eventually create some desirable traits in plants and develop new cultivars. In this case, the PLT5 regulator can help deliver this toolbox and help grow young leaves or stems into new plants carrying these desirable traits.

More than 20 scientists across Florida including Huo are part of the UF/IFAS Plant Breeding team. They develop new varieties of citrus, tomatoes, strawberries, blueberries, cattle forages, peanuts, sugarcane, ornamental plants, and more.

Source: ifas.ufl.edu

Link:
UF scientists may have found a way to more efficiently apply genome editing to plant breeding - hortidaily.com

Katiyar, A. et al. Genomic profiling of antimicrobial resistance genes in clinical isolates of Salmonella typhi from patients infected with typhoid fever in India. Sci. Rep. 10, 8299 (2020).

ADS CAS PubMed PubMed Central Article Google Scholar

Nordmann, P. & Poirel, L. Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria. Clin. Infect. Dis. 69, S521S528 (2019).

CAS PubMed PubMed Central Article Google Scholar

Manandhar, S. et al. A high prevalence of multi-drug resistant Gram-negative bacilli in a Nepali tertiary care hospital and associated widespread distribution of Extended-Spectrum Beta-Lactamase (ESBL) and carbapenemase-encoding genes. Ann. Clin. Microbiol. Antimicrob. 19, 48 (2020).

CAS PubMed PubMed Central Article Google Scholar

Wyres, K. L. et al. Genomic surveillance for hypervirulence and multi-drug resistance in invasive Klebsiella pneumoniae from South and Southeast Asia. Genome Med. 12, 11 (2020).

CAS PubMed PubMed Central Article Google Scholar

World Health Organization. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities (WHO, 2017).

Google Scholar

Zavascki, A. P., Bulitta, J. B. & Landersdorfer, C. B. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev. Anti. Infect. Ther. 11, 13331353 (2013).

CAS PubMed Article Google Scholar

Karampatakis, T. et al. Molecular epidemiology of endemic carbapenem-resistant Gram-negative bacteria in an intensive care unit. Microb. Drug Resist. 25, 712716 (2018).

PubMed Article CAS Google Scholar

Nair, S. et al. ESBL-producing strains isolated from imported cases of enteric fever in England and Wales reveal multiple chromosomal integrations of blaCTX-M-15 in XDR Salmonella Typhi. J. Antimicrob. Chemother. 76, 14591466 (2021).

CAS PubMed Article Google Scholar

Zagui, G. S. et al. Gram-negative bacteria carrying -lactamase encoding genes in hospital and urban wastewater in Brazil. Environ. Monit. Assess. 192, 376 (2020).

CAS PubMed Article Google Scholar

Elbadawi, H. S. et al. Detection and characterization of carbapenem resistant Gram negative bacilli isolates recovered from hospitalized patients at Soba University Hospital, Sudan. BMC Microbiol. 21, 136 (2021).

CAS PubMed PubMed Central Article Google Scholar

Sawa, T., Kooguchi, K. & Moriyama, K. Molecular diversity of extended-spectrum -lactamases and carbapenemases, and antimicrobial resistance. J. Intensive Care 8, 13 (2020).

PubMed PubMed Central Article Google Scholar

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 22th Informational Supplement (CLSI, 2012).

Google Scholar

Altoparlak, U., Aktas, F., Celebi, D., Ozkurt, Z. & Akcay, M. N. Prevalence of metallo-beta-lactamase among Pseudomonas aeruginosa and Acinetobacter baumannii isolated from burn wounds and in vitro activities of antibiotic combinations against these isolates. Burns 31(6), 707710 (2005).

PubMed Article Google Scholar

Song, W. et al. Detection of extended spectrum -lactamases by using boronic-acid as an AmpC -lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli. J. Clin. Microbiol. 45, 118084 (2007).

CAS PubMed PubMed Central Article Google Scholar

Lee, K. et al. Modified Hodge and EDTA-disk synergy tests to screen metallo--lactamase-producing strains of Pseudomonas and Acinetobactet species. Clin. Microbiol. Infect. 7, 8891 (2001).

CAS PubMed Article Google Scholar

Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30, 21142120 (2014).

CAS PubMed PubMed Central Article Google Scholar

Zerbino, D. R. & Birney, E. Velvet: Algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 18, 821829 (2008).

CAS PubMed PubMed Central Article Google Scholar

Gurevich, A., Saveliev, V., Vyahhi, N. & Tesler, G. QUAST: Quality assessment tool for genome assemblies. Bioinformatics 29, 10721075. https://doi.org/10.1093/bioinformatics/btt086 (2013).

CAS Article PubMed PubMed Central Google Scholar

Seemann, T. Prokka: Rapid prokaryotic genome annotation. Bioinformatics 30, 20682069. https://doi.org/10.1093/bioinformatics/btu153 (2014).

CAS Article PubMed Google Scholar

Meletis, G. Carbapenem resistance: Overview of the problem and future perspectives. Ther. Adv. Infect. Dis. 3, 1521 (2015).

Google Scholar

Sands, K. et al. Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. Nat. Microbiol. 6, 512523 (2021).

PubMed PubMed Central Article CAS Google Scholar

Fonseca, F. et al. The basis for carbapenem hydrolysis by class A -lactamases: A combined investigation using crystallography and simulations. J. Am. Chem. Soc. 134, 1827518285 (2012).

CAS PubMed Article Google Scholar

Satyajeet, K. et al. Carbapenemresistant Enterobacteriaceae: Prevalence and bacteriological profile in a tertiary teaching hospital from rural western India. Indian J. Microbiol. Res. 2020, 7400 (2020).

Google Scholar

Wattal, C. et al. Impact of informational feedback to clinicians on antibiotic-prescribing rates in a tertiary care hospital in Delhi. Indian J. Med. Microbiol. 33, 255259 (2015).

CAS PubMed Article Google Scholar

Gupta, R., Malik, A., Rizvi, M. & Ahmed, M. Presence of metallo-beta-lactamases (MBL), extended-spectrum beta-lactamase (ESBL) & AmpC positive non-fermenting Gram-negative bacilli among Intensive Care Unit patients with special reference to molecular detection of bla(CTX-M) & bla(AmpC) genes. Indian J. Med. Res. 144, 271275 (2016).

CAS PubMed PubMed Central Article Google Scholar

Rohit, A. et al. CTX-M type extended-spectrum & #946;-lactamase in Escherichia coli isolated from extra-intestinal infections in a tertiary care hospital in south India. Indian J. Med. Res. 149, 281284 (2019).

CAS PubMed PubMed Central Article Google Scholar

Muzaheed, et al. High prevalence of CTX-M-15-producing Klebsiella pneumoniae among inpatients and outpatients with urinary tract infection in Southern India. J. Antimicrob. Chemother. 61, 13931394 (2008).

CAS PubMed PubMed Central Article Google Scholar

Devi, L. et al. Increasing prevalence of Escherichia coli and Klebsiella pneumoniae producing CTX-M-type extended-spectrum beta-lactamase, carbapenemase, and NDM-1 in patients from a rural community with community acquired infections: A 3-year study. Int. J. Appl. Basic Med. Res. 10, 156163 (2020).

CAS PubMed PubMed Central Article Google Scholar

Khan, E. R. et al. Prevalence and molecular epidemiology of clinical isolates of Escherichia coli and Klebsiella pneumoniae harboring extended-spectrum beta-lactamase and carbapenemase genes in Bangladesh. Microb. Drug Resist. 24, 15681579 (2018).

CAS PubMed Article Google Scholar

Rocha, F. R., Pinto, V. P. T. & Barbosa, F. C. B. The spread of CTX-M-type extended-spectrum -lactamases in Brazil: A systematic review. Microb. Drug Resist. 22, 301311 (2015).

PubMed Article CAS Google Scholar

Xia, S. et al. Dominance of CTX-M-type extended-spectrum -lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China. PLoS ONE 9, e100707e100707 (2014).

ADS PubMed PubMed Central Article CAS Google Scholar

Abrar, S. et al. Distribution of blaCTX M, blaTEM, blaSHV and blaOXA genes in extended-spectrum--lactamase-producing clinical isolates: A three-year multi-center study from Lahore, Pakistan. Antimicrob. Resist. Infect. Control 8, 80 (2019).

PubMed PubMed Central Article Google Scholar

Zeynudin, A. et al. Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum -lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia. BMC Infect. Dis. 18, 524 (2018).

CAS PubMed PubMed Central Article Google Scholar

Yuki, S. et al. Environmental presence and genetic characteristics of carbapenemase-producing enterobacteriaceae from hospital sewage and river water in the Philippines. Appl. Environ. Microbiol. 86, e01906-e1919 (2021).

Google Scholar

Marie-Frdrique, L. et al. Extended-spectrum -lactamases of the CTX-M type now in Switzerland. Antimicrob. Agents Chemother. 51, 28552860 (2007).

Article CAS Google Scholar

Quinteros, M. et al. Extended-Spectrum -lactamases in enterobacteriaceae in Buenos Aires, Argentina, Public Hospitals. Antimicrob. Agents Chemother. 47, 28642867 (2003).

CAS PubMed PubMed Central Article Google Scholar

Al Naiemi, N. et al. Widely distributed and predominant CTX-M extended-spectrum -lactamases in Amsterdam, The Netherlands. J. Clin. Microbiol. 44, 30123014 (2006).

CAS PubMed PubMed Central Article Google Scholar

Zhao, W.-H. & Hu, Z.-Q. Epidemiology and genetics of CTX-M extended-spectrum -lactamases in Gram-negative bacteria. Crit. Rev. Microbiol. 39, 79101 (2013).

CAS PubMed Article Google Scholar

Pokhrel, R. H., Thapa, B., Kafle, R., Shah, P. K. & Tribuddharat, C. Co-existence of beta-lactamases in clinical isolates of Escherichia coli from Kathmandu, Nepal. BMC Res. Notes 7, 694 (2014).

PubMed PubMed Central Article CAS Google Scholar

Laurent, P., de la Ortiz, R.J.-M., Anas, R., Marta, A.-S. & Patrice, N. CTX-M-33 Is a CTX-M-15 derivative conferring reduced susceptibility to carbapenems. Antimicrob. Agents Chemother. 63, e01515-19 (2021).

Google Scholar

Walsh, T. R. Emerging carbapenemases: A global perspective. Int. J. Antimicrob. Agents 36, S8S14 (2010).

CAS PubMed Article Google Scholar

Nachimuthu, R. et al. Characterization of carbapenem-resistant Gram-negative bacteria from Tamil Nadu. J. Chemother. 28, 371374 (2016).

CAS PubMed Article Google Scholar

Kazi, M. et al. Molecular characterization of carbapenem-resistant Enterobacteriaceae at a tertiary care laboratory in Mumbai. Eur. J. Clin. Microbiol. Infect. Dis. 34, 467472 (2015).

CAS PubMed Article Google Scholar

Okoche, D., Asiimwe, B. B., Katabazi, F. A., Kato, L. & Najjuka, C. F. Prevalence and characterization of carbapenem-resistant enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS ONE 10, e0135745 (2015).

PubMed PubMed Central Article CAS Google Scholar

Mushi, M. F., Mshana, S. E., Imirzalioglu, C. & Bwanga, F. Carbapenemase genes among multidrug resistant gram negative clinical isolates from a Tertiary Hospital in Mwanza, Tanzania. Biomed Res. Int. 2014, 303104 (2014).

PubMed PubMed Central Article CAS Google Scholar

Hornsey, M., Phee, L. & Wareham, D. W. A novel variant, NDM-5, of the New Delhi metallo--lactamase in a multidrug-resistant Escherichia coli ST648 isolate recovered from a patient in the United Kingdom. Antimicrob. Agents Chemother. 55, 59525954 (2011).

CAS PubMed PubMed Central Article Google Scholar

Liang, W. et al. Emergence and mechanism of carbapenem-resistant Escherichia coli in Henan, China, 2014. J. Infect. Public Health 11, 347351 (2018).

PubMed Article Google Scholar

Kopotsa, K., Sekyere, J. O. & Mbelle, N. Characterization of plasmids mediating carbapenem-resistance in Klebsiella pneumoniae in Pretoria, South Africa. Int. J. Infect. Dis. 101, 14 (2020).

Article Google Scholar

Mmatli, M., Mbelle, N. M., Maningi, N. E. & Osei Sekyere, J. Emerging transcriptional and genomic mechanisms mediating carbapenem and polymyxin resistance in enterobacteriaceae: A systematic review of current reports. mSystems 5, e007830 (2020).

Article Google Scholar

Rawat, D. & Nair, D. Extended-spectrum & #223;-lactamases in gram negative bacteria. J. Glob. Infect. Dis. 2, 263274 (2010).

PubMed PubMed Central Article Google Scholar

See original here:
Genome-wide identification of carbapenem-resistant Gram-negative bacterial (CR-GNB) isolates retrieved from hospitalized patients in Bihar, India |...

In VAs Million Veteran Program, researchers are mapping the human genome by using genotypinga process that spells out several hundred thousand data points, one-by-one. (Photo for illustrative purposes only Getty Images/alanphillips)

May 19, 2022

By Mike Richman VA Research Communications

"The importance of this cannot be overstated. Using TOPMed's imputation panel vastly enriches MVP's genetic database."

Since 2011, more than 875,000 Veterans have donated their DNA to the VA Million Veteran Program (MVP). In the program, VA researchers are sequencing Veterans' genomesa complete set of genetic materialto better understand how genes, lifestyles, and military exposures can affect a persons health and risk for illness.

Centrifugation helps scientists extract DNA from a Veteran's blood sample and prepare the DNA for genetic analysis, either through genotyping or whole genome sequencing.

Centrifugation helps scientists extract DNA from a Veteran's blood sample and prepare the DNA for genetic analysis, either through genotyping or whole genome sequencing.

Researchers map the genomes using genotypinga process that spells out several hundred thousand data points, one-by-one. To fill in any missing data, scientists look to genomes where all data points have been fully sequenced. These genomes are used as a reference to determine the missing letters.

MVP has created whole genome sequences for over 140,000 Veterans. However, it takes time to process this large amount of data and make it available for research. It takes even more time to develop a calculation toolcalled an imputation panelto determine the missing data points that remain when genotyping is complete.

In efforts to find a more accurate and cost-effective method for predicting missing genomic data points, VA investigators found a potential interim solution just across town in Bethesda, Maryland: a genomic research program at the National Institutes of Health (NIH).

As part of that solution, MVP has been collaborating with NIH to use a reference panel for imputation.

The panel is run by TOPMedthe Trans-Omics for Precision Medicine Program. The program, funded by NIHs National Heart, Lung, and Blood Institute (NHLBI), aims to generate scientific resources that will improve the understanding of heart, lung, blood, and sleep disorders and advance precision medicine, an approach in health care that takes into account a persons gene variants and his or her environment and lifestyle to find the right treatment.

Since 2014, TOPMed has collected the entire genome sequence of more than 100,000 people. Scientists created a new reference genome and imputation panel based off these whole-genome sequences.

This first-of-its kind imputation panel offers far more statistical accuracy than any previous imputation panels. In that way, it will help scientists develop better treatments specific to a persons genes and environment.

MVP wanted to find a way to use this tool to improve its genetic database, now one of the largest in the world. The database supports the work of more than 500 researchers across VA. With better genetic data, the researchers can uncover new genetic markers associated with disease in Veterans that could someday revolutionize their health care. As such, MVP leaders set out to strike up a partnership with their colleagues in Bethesda.

In 2018, TOPMed and VA began discussions with the goal of using this new imputation panel to re-do genetic analysis on DNA shared by hundreds of thousands of Veterans in MVP.

The importance of this cannot be overstated, says Dr. Phil Tsao, MVPs co-principal investigator in data generation and access. Using TOPMeds imputation panel vastly enriches MVPs genetic database. Over 500 researchers use MVP data to find new genetic markers related to health and illness in Veterans. With better data, they can make better findings. With better findings, we can offer Veterans better care with more laser-focused accuracy.

The TOPMed reference genome for this imputation panel was selected with racial and ethnic diversity in mind. This means VA can make much more accurate sequencing predictions for people who come from non-European ancestry. This is critical for MVP, since approximately 30% of the more than 875,000 Veterans in MVP are from non-European descent.

To be able to more accurately assemble their genome means the research we do on non-European Veteran populations will be much more thorough, says Dr. Sumitra Muralidhar, the director of MVP. That means we can discover new, never-before-known genetic markers connected with health and disease in Veteran populations of non-European descent.

In 2020, VA acquired the TOPMed imputation panel from NIH, and researchers began methodically re-analyzing and updating more than 650,000 genomes from Veterans who provided blood samples when they joined MVP. In December 2021, the update was complete and the new, upgraded data on hundreds of thousands of Veterans became available to research.

Due to our collaboration with TOPMed, we have better genetic data now, which will hopefully lead to findings of new genetic markers for diseases, specifically in diverse Veterans, Muralidhar says. The end result will hopefully be new discoveries and better treatments, as well as a better understanding of the biology of diseases. That way, we can offer more precise treatments for diseases and other health conditions.

Now that MVPs genetic data is updated with TOPMeds reference panel, any findings from MVP data can becompared and validated with findings from other research based on genomes that were also imputed using TOPMeds reference panel.

Use of the TOPMed reference panel in MVP, which is one of the worlds largest genomic biobanks, allows for more collaboration between NIH and VA scientists to cross-validate each others analysis results, says Dr. Saiju Pyarajan, director of the Center for Data and Computational Sciences at the VA Boston Healthcare System. The more people around the world who have been compared to the same reference sample, the more were able to drastically increase the confidence in the conclusions or results from these genomic analyses. This is wonderful for the future of precision medicine.

VA Research Currents archives || Sign up for VA Research updates

Continue reading here:
Mapping out the human genome - VA's Office of Research and Development